Related Experiment Video
Updated: Jul 1, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
ESR1 amplification in endometrial carcinomas: hope or hyperbole?
D S P Tan1, M B K Lambros, C Marchiò
1Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK.
The Journal of Pathology
|September 13, 2008
Summary
ESR1 gene amplification may drive oestrogen receptor alpha expression in breast and endometrial cancers. This review discusses methods for identifying ESR1 amplification and its controversial role in carcinogenesis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The ESR1 gene encodes oestrogen receptor alpha (ERα), crucial in breast and endometrial cancer development.
- Recent findings suggest ESR1 gene amplification may drive ERα expression, potentially as an early carcinogenic event.
- The prevalence and clinical significance of 6q copy number gains, including ESR1 amplification, remain debated.
Purpose of the Study:
- To review methodologies for identifying ESR1 amplification.
- To discuss current literature and controversies surrounding ESR1 amplification in breast and endometrial cancers.
- To clarify the role of ESR1 amplification in cancer development.
Main Methods:
- Literature review of studies identifying ESR1 amplification.
- Analysis of methodologies used for copy number variation detection.
- Discussion of conflicting findings and ongoing debates.
Main Results:
- ESR1 amplification is a proposed mechanism for elevated ERα expression in certain cancers.
- Methods for detecting ESR1 amplification vary, contributing to discrepancies in reported prevalence.
- The clinical implications of ESR1 amplification require further investigation.
Conclusions:
- Clarifying detection methods is essential for understanding ESR1 amplification.
- Further research is needed to establish the precise role and clinical impact of ESR1 amplification in breast and endometrial carcinogenesis.
- Addressing controversies will advance the field of ERα-driven cancer research.
